Key result
Cardiovascular comorbidity in patients undergoing surgery for early-stage NSCLC was associated with significantly lower 5-year survival compared to those without comorbidity (35.5% vs 56.4%, P=0.01).
Why the study?
Does coexisting cardiovascular disease worsen survival and morbidity in patients undergoing surgery for stage I and II non-small-cell lung cancer?
Cohort (n=247)
Does coexisting cardiovascular disease worsen survival and morbidity in patients undergoing surgery for stage I and II non-small-cell lung cancer?
Absolute Event Rate: 35.5% vs 56.4%
p-value: p=0.01
Coexisting cardiovascular disease, particularly multifocal vascular disease, significantly reduces survival and increases morbidity in patients undergoing surgery for early-stage non-small-cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Cardiovascular comorbidity signals higher post-resection mortality in early NSCLC; leaves open whether targeted CV optimization improves survival.
Ambrogi et al. (2003) conducted a cohort in Stage I and II non-small-cell lung cancer (n=247). Cardiovascular comorbidity vs. No cardiovascular comorbidity was evaluated on 5-year survival rate (p=0.01). Cardiovascular comorbidity in patients undergoing surgery for early-stage NSCLC was associated with significantly lower 5-year survival compared to those without comorbidity (35.5% vs 56.4%, P=0.01).
Synapse has enriched one closely related paper. Consider it for comparative context: